Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 fluvoxamine studies
00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies63%0.37 [0.09-1.47]17/89632/85363% improvement3 fluvoxamine COVID-19 studiesc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.65; I​2 = 35.2%; Z = 1.41Effect extraction pre-specifiedFavors fluvoxamineFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)29%0.71 [0.37-1.29]17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies29%0.71 [0.38-1.30]17/73924/73329% improvement1 fluvoxamine COVID-19 mortality resultc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.11Favors fluvoxamineFavors control 00.250.50.7511.251.51.752+Lenze (DB RCT)82%0.18 [0.02-1.50]hosp.1/805/72Improvement, RR [CI]TreatmentControlSeftel (QR)94%0.06 [0.00-1.04]hosp.0/776/48Tau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.02-0.67]1/15711/12088% improvementReis (DB RCT)21%0.79 [0.59-1.06]hosp.74/73992/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment21%0.79 [0.59-1.06]74/73992/73321% improvementAll studies67%0.33 [0.07-1.52]75/896103/85367% improvement3 fluvoxamine COVID-19 hospitalization resultsc19fluvoxamine.com Sep 24, 2021Tau​2 = 1.11; I​2 = 59.0%; Z = 1.43Favors fluvoxamineFavors control 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies63%0.37 [0.09-1.47]17/89632/85363% improvement3 fluvoxamine COVID-19 serious outcomesc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.65; I​2 = 35.2%; Z = 1.41Effect extraction pre-specifiedFavors fluvoxamineFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)-37%1.37 [0.88-2.13]viral+173/218160/217Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-37%1.37 [0.88-2.13]173/218160/217-37% improvementAll studies-37%1.37 [1.23-1.52]173/218160/217-37% improvement1 fluvoxamine COVID-19 viral clearance resultc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 5.91Favors fluvoxamineFavors control 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment93%0.07 [0.00-1.28]0/806/7293% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies64%0.36 [0.05-2.74]17/81930/80564% improvement2 fluvoxamine COVID-19 Randomized Controlled Trialsc19fluvoxamine.com Sep 24, 2021Tau​2 = 1.46; I​2 = 56.7%; Z = 0.99Effect extraction pre-specifiedFavors fluvoxamineFavors control 00.250.50.7511.251.51.752+Reis (DB RCT)29%0.71 [0.37-1.29]17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies29%0.71 [0.38-1.30]17/73924/73329% improvement1 fluvoxamine COVID-19 RCT mortality resultc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.11Favors fluvoxamineFavors control 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementAll studies89%0.11 [0.01-0.85]0/1578/12089% improvement2 fluvoxamine COVID-19 peer reviewed trialsc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.12Effect extraction pre-specifiedFavors fluvoxamineFavors control 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlLenze (DB RCT)82%0.18 [0.02-1.50]hosp.1/805/72Seftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Seftel (QR)94%0.06 [0.00-1.04]hosp.0/776/48Seftel (QR)99%0.01 [0.00-0.21]no recov.0/7729/48Reis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Reis (DB RCT)21%0.79 [0.59-1.06]hosp.74/73992/733Reis (DB RCT)66%0.34 [0.20-0.54]hosp./ER541 (n)609 (n)Reis (DB RCT)29%0.71 [0.54-0.93]hosp./ER77/739108/733Reis (DB RCT)32%0.68 [0.50-0.91]hosp./ER77/728108/722Reis (DB RCT)-37%1.37 [0.88-2.13]viral+173/218160/217fluvoxamine COVID-19 outcomesc19fluvoxamine.com Sep 24, 2021Favors fluvoxamineFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit